Sanofi reported over €1.03 billion in impairment charges tied largely to the termination of an eczema drug program, and said its pipeline review resulted in wind-downs of two additional immunology assets. The company disclosed that the second-quarter impairment included €1B+ write-offs and followed a portfolio reassessment across immunology. The decision reflects continued pressure to reshape development pipelines amid clinical setbacks and shifting expectations for competitive immunology targets. Sanofi’s CEO-level strategic reset continues to emphasize late-stage focus and a tighter clinical portfolio. Separate reporting also indicates Sanofi’s new leadership is looking closely at late-stage pipeline structure as it works to counter prior clinical clearouts.